Does Guanfacine Attenuate Stress-Induced Drinking?

Therapuetic Areas:Psychiatry / Psychology
Age Range:21 - 65
Start Date:June 2014
End Date:January 2020
Contact:Andrew Bessette

Use our guide to learn which trials are right for you!

Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize
that guanfacine versus placebo will decrease the number of drinks consumed during the 2-hour
self-administration period across stress and neutral/relaxing conditions.

Inclusion Criteria:

- Age 21-65

- Able to read and write English

- Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for
current (past 6 months) alcohol abuse or alcohol dependence

Exclusion Criteria:

- Participants with any significant current medical conditions, seizures, delirium or
hallucinations, or other unstable medical conditions including HIV

- Current DSM-IV abuse or dependence on substances, other than alcohol abuse, alcohol
dependence, or nicotine dependence

- Women who are pregnant or nursing

- Suicidal, homicidal or evidence of current (past 6-month) mental illness

- Meet DSM-IV criteria for current (past-6 month) attention deficit hyperactivity
disorder (ADHD)

- Specific exclusions for administration of guanfacine not already specified include:
EKG evidence at baseline screening of any clinically significant conduction
abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker;
history of fainting, syncopal attacks, heart failure or myocardial infarction, or
impaired liver as indicated by aspartate aminotransferase (AST), alanine
aminotransferase (ALT) > 3x normal or renal function (estimated creatinine clearance
<60 cc/min); treatment with any antihypertensive drug or any alpha-adrenergic blocker;
use of any central nervous system (CNS) depressant (e.g., phenothiazines,
barbiturates, benzodiazepines)

- Subjects likely to exhibit clinically significant alcohol withdrawal during the study.

- Individuals who are seeking treatment for drinking
We found this trial at
New Haven, Connecticut 06519
Principal Investigator: Sherry A McKee, PhD
Phone: 203-737-3554
New Haven, CT
Click here to add this to my saved trials